Ieto J: Gene therapy of liver cancer. World J Gastroenterol 2006, 12:6085-6097. 2. Breakthrough of

Ieto J: Gene therapy of liver cancer. World J Gastroenterol 2006, 12:6085-6097. 2. Breakthrough of the year. The runners-up. Science 2009, 326:1600-1607. 3. Liu XY: Targeting gene-virotherapy of cancer and its prosperity. Cell Res 2006, 16:879-886. 4. Kozarsky KF, Wilson JM: Gene therapy: adenovirus vectors. Curr Opin Genet Dev 1993, 3:499-503. 5. Alemany R, Balague C, Curiel DT: Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000, 18:723-727. 6. Zhang ZL, Zou WG, Luo CX, Li BH, Wang JH, Sun LY, Qian QJ, Liu XY: An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res 2003, 13:481-489. 7. O’Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A, Boyle L, Pandey K, Soria C, Kunich J, Shen Y, Habets G, Ginzinger D, McCormick F: Late viral RNA export, rather than p53 inactivation, determines ONYX015 tumor selectivity. Cancer Cell 2004, 6:611-623. 8. Hallenbeck PL, Chang YN, Hay C, Golightly D, Stewart D, Lin J, Phipps S, Chiang YL: A novel tumor-specific replication-restricted PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/27872238 adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther 1999, 10:1721-1733. 9. Tangkijvanich P, Anukulkarnkusol N, Suwangool P, Lertmaharit S, Hanvivatvong O, Kullavanijaya P, Poovorawan Y: Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alphafetoDihexaMedChemExpress Dihexa protein levels. J Clin Gastroenterol 2000, 31:302-308. 10. Li Y, Yu DC, Chen Y, Amin P, Zhang H, Nguyen N, Henderson DR: A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res 2001, 61:6428-6436. 11. Arbuthnot P, Bralet MP, Thomassin H, Danan JL, Brechot C, Ferry N: Hepatoma cell-specific expression of a retrovirally transferred gene is achieved by alpha-fetoprotein but not insulinlike growth factor II regulatory sequences. Hepatology 1995, 22:1788-1796. 12. Arbuthnot PB, Bralet MP, Le Jossic C, Dedieu JF, Perricaudet M, Brechot C, Ferry N: In vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector. Hum Gene Ther 1996, 7:1503-1514. 13. Danen-Van Oorschot AA, Fischer DF, Grimbergen JM, Klein B, Zhuang S, Falkenburg JH, Backendorf C, Quax PH, Van der Eb AJ, Noteborn MH: Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells. Proc Natl Acad Sci USA 1997, 94:5843-5847. 14. Zhuang SM, Shvarts A, van Ormondt H, Jochemsen AG, van der Eb AJ, Noteborn MH: Apoptin, a protein derived from chicken anemia virus, induces p53-independent apoptosis in human osteosarcoma cells. Cancer Res 1995, 55:486-489. 15. Danen-Van Oorschot AA, Zhang Y, Erkeland SJ, Fischer DF, van der Eb AJ, Noteborn MH: The effect of Bcl-2 on Apoptin in `normal’ vs transformed human cells. Leukemia 1999, 13(Suppl 1):S75-77. 16. Burek M, Maddika S, Burek CJ, Daniel PT, Schulze-Osthoff K, Los M: Apoptininduced cell death is modulated by Bcl-2 family members and is Apaf-1 dependent. Oncogene 2006, 25:2213-2222. 17. Danen-Van Oorschot AA, van der Eb AJ, Noteborn MH: BCL-2 stimulates Apoptin-induced apoptosis. Adv Exp Med Biol 1999, 457:245-249. 18. Guelen L, Paterson H, Gaken J, Meyers M, Farzaneh F, Tavassoli M: TATapoptin is efficiently delivered and induces apoptosis in cancer cells. Oncogene 2004, 23:1153-1165.Conclusion AD55-Apoptin was successfully generated and more powerful and safe on hepatocarcinoma therapy than AD55 or even classical ONYX-015. It throws some light on the s.